When it comes to the hottest cosmetic ingredients at the moment, recombinant collagen is well deserved. However, what consumers are not familiar with is that before the advent of recombinant collagen, animal-derived collagen dominated the market, and its safety was questioned while solving problems for the skin. The emergence of recombinant collagen not only brings a new skin care solution to the skin, but also leads the development vane of the industry. Today, as a global leader in recombinant collagen, Giant Biotech is actively engaged in the construction of the industry while paying attention to its own development.
The research on recombinant collagen can be traced back to 2000. A research team from Northwest University in China has realized the laboratory test expression of recombinant collagen (type I.) using a prokaryotic cell system (Escherichia coli). In the same year, in order to promote the industrialization of this scientific research achievement, Giant Biotech was established. It is reported that the recombinant collagen independently developed by Giant Bio is 100% consistent with the amino acid sequence of human collagen, which can effectively avoid the problems of unsatisfactory effect and rejection of animal-derived collagen, and revolutionarily improve the safety and effectiveness of collagen. In the subsequent research and development process, Giant Biotech did not stop. In 2021, the Human-like recombinant collagen C5HA biomimetic combination technology ingredient was upgraded to further enhance the functional effect. Today, there are more than 40 kinds of collagen molecules in the recombinant collagen molecular library of Giant Bio, and it continues to maintain a leading position in the industry. In addition, it has also successfully promoted the R&D and registration of 4 recombinant collagen skin rejuvenation products.
After more than 20 years of continuous cultivation in the field of recombinant collagen, Giant Biotech has 93 patents and patent applications so far, and 13 new patents will be added in 2023. With its strong scientific research capabilities and product innovation capabilities, last year, Juzi Biotech achieved an operating income of 3.524 billion yuan, a year-on-year increase of 49%, and a net profit of 1.452 billion yuan, a year-on-year increase of 44.9%.
In order to further standardize the development of the market, Giant Bio took the initiative to play an exemplary role in the industry, and jointly issued the "Giant 3.15 Transparency Commitment" with two major official media such as Xinhuanet and People's Health to protect the rights and interests of consumers and further promote the transparency of information on recombinant collagen products. From March 16th to 24th, Juzi Biotech was invited to participate in the 23rd Shanghai International Plastic and Cosmetic Surgery Conference and the 13th Shanghai Plastic Surgery Forum, participated in the recombinant collagen seminar, and discussed with industry leaders at home and abroad to help the high-quality development of the industry.
In the 2024 "3.15" International Consumer Rights Day "Product and Service Quality Integrity Commitment" activity, Giant Biotech won a number of awards with its advanced technology, excellent quality and good reputation, giving full play to the leading role of an excellent enterprise and promoting the healthy development of the industry.
Although recombinant collagen is still in the early stage of development, Giant Bio will continue to invest in R&D and launch more new products and raw materials to make recombinant collagen better serve consumers. We are willing to join hands with more peers to help the long-term development of the industry.